Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/31931
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMEHTA, Ravindra L.
dc.contributor.authorAWDISHU, Linda
dc.contributor.authorDAVENPORT, Andrew
dc.contributor.authorMURRAY, Patrick T.
dc.contributor.authorMACEDO, Etienne
dc.contributor.authorCERDA, Jorge
dc.contributor.authorCHAKARAVARTHI, Raj
dc.contributor.authorHOLDEN, Arthur L.
dc.contributor.authorGOLDSTEIN, Stuart L.
dc.date.accessioned2019-05-30T13:45:22Z
dc.date.available2019-05-30T13:45:22Z
dc.date.issued2015
dc.identifier.citationKIDNEY INTERNATIONAL, v.88, n.2, p.226-234, 2015
dc.identifier.issn0085-2538
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/31931
dc.description.abstractDrug-induced kidney disease is a frequent cause of renal dysfunction; however, there are no standards to identify and characterize the spectrum of these disorders. We convened a panel of international, adult and pediatric, nephrologists and pharmacists to develop standardized phenotypes for drug-induced kidney disease as part of the phenotype standardization project initiated by the International Serious Adverse Events Consortium. We propose four phenotypes of drug-induced kidney disease based on clinical presentation: acute kidney injury, glomerular, tubular, and nephrolithiasis, along with the primary and secondary clinical criteria to support the phenotype definition, and a time course based on the KDIGO/AKIN definitions of acute kidney injury, acute kidney disease, and chronic kidney disease. Establishing causality in drug-induced kidney disease is challenging and requires knowledge of the biological plausibility for the specific drug, mechanism of injury, time course, and assessment of competing risk factors. These phenotypes provide a consistent framework for clinicians, investigators, industry, and regulatory agencies to evaluate drug nephrotoxicity across various settings. We believe that this is the first step to recognizing drug-induced kidney disease and developing strategies to prevent and manage this condition.eng
dc.description.sponsorshipInternational Serious Adverse Events Consortium
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUPeng
dc.relation.ispartofKidney International
dc.rightsrestrictedAccesseng
dc.subjectacute kidney injuryeng
dc.subjectadverse reactioneng
dc.subjectdrugseng
dc.subjectglomerulonephritiseng
dc.subjecthypersensitivityeng
dc.subjectnephrotoxicityeng
dc.subject.otherexperienceeng
dc.subject.otherinjuryeng
dc.subject.otherakieng
dc.titlePhenotype standardization for drug-induced kidney diseaseeng
dc.typearticleeng
dc.rights.holderCopyright NATURE PUBLISHING GROUPeng
dc.identifier.doi10.1038/ki.2015.115
dc.identifier.pmid25853333
dc.subject.wosUrology & Nephrologyeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalMEHTA, Ravindra L.:Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
hcfmusp.author.externalAWDISHU, Linda:Univ Calif San Diego, Skaggs Sch Pharm, La Jolla, CA 92093 USA
hcfmusp.author.externalDAVENPORT, Andrew:Royal Free Hosp, London NW3 2QG, England; UCL, Sch Med, UCL Ctr Nephrol, London W1N 8AA, England
hcfmusp.author.externalMURRAY, Patrick T.:Univ Coll Dublin, Hlth Sci Ctr, Sch Med & Med Sci, Dublin 2, Ireland
hcfmusp.author.externalCERDA, Jorge:Albany Med Coll, Albany, NY 12208 USA
hcfmusp.author.externalCHAKARAVARTHI, Raj:Care Hosp, Hyderabad, Telangana, India
hcfmusp.author.externalHOLDEN, Arthur L.:Int Serious Adverse Event Consortium, Chicago, IL USA
hcfmusp.author.externalGOLDSTEIN, Stuart L.:Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH USA
hcfmusp.description.beginpage226
hcfmusp.description.endpage234
hcfmusp.description.issue2
hcfmusp.description.volume88
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000358783000006
hcfmusp.origem.id2-s2.0-84938552326
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAithal GP, 2011, CLIN PHARMACOL THER, V89, P806, DOI 10.1038/clpt.2011.58eng
hcfmusp.relation.referenceK.D.I.G.O.K.A.K.I.W. Group, 2012, KIDNEY INT, V2, P1eng
hcfmusp.relation.referenceKoyner JL, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-105eng
hcfmusp.relation.referenceMcCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297eng
hcfmusp.relation.referenceMehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.xeng
hcfmusp.relation.referenceMoffett BS, 2011, CLIN J AM SOC NEPHRO, V6, P856, DOI 10.2215/CJN.08110910eng
hcfmusp.relation.referenceNARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154eng
hcfmusp.relation.referencePark YH, 2005, PEDIATR NEPHROL, V20, P1126, DOI 10.1007/s00467-005-1915-8eng
hcfmusp.relation.referenceSelby NM, 2012, CLIN J AM SOC NEPHRO, V7, P533, DOI 10.2215/CJN.08970911eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1523-1755
hcfmusp.citation.scopus93-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_MEHTA_Phenotype_standardization_for_druginduced_kidney_disease_2015.PDF
  Restricted Access
publishedVersion (English)314.16 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.